Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327545 | 0.86 | BACE1 (0.34) | BACE1 | |
| SCHEMBL2430707 | 0.85 | PDK1 (0.40) | PDK1PDK2PDK3PDK4BACE1 | |
| SCHEMBL14248548 | 0.85 | BACE1 (0.36) | BACE1 | |
| SCHEMBL12293420 | 0.84 | PDK1 (0.39) | PDK1PDK2PDK3PDK4BACE1 | |
| SCHEMBL2437418 | 0.83 | BACE1 (0.43) | PDK1PDK2PDK3PDK4BACE1 | |
| SCHEMBL2433096 | 0.83 | BACE1 (0.42) | PDK1PDK2PDK3PDK4BACE1 | |
| SCHEMBL2438315 | 0.83 | BACE1 (0.42) | PDK1PDK2PDK3PDK4BACE1 | |
| SCHEMBL7716003 | 0.82 | BACE1 (0.44) | PDK1PDK2PDK3PDK4BACE1 | |
| SCHEMBL2555754 | 0.82 | BACE1 (0.44) | PDK1PDK2PDK3PDK4BACE1 | |
| SCHEMBL2435120 | 0.81 | PDK1 (0.40) | PDK1PDK2PDK3PDK4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | BACE1, BACE2, APH1B | PDK1 3030/4885PDK2 3827/4885PDK3 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.